Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Koninklijke Philips N.V.
  6. News
  7. Summary
    PHIA   NL0000009538

KONINKLIJKE PHILIPS N.V.

(PHIA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Koninklijke Philips N : Royal Philips - Five-year patient-level meta-analysis of ILLUMENATE EU RCT and Pivotal study results confirms safety profile of Philips Stellarex .035' low-dose Drug-Coated Balloon

04/21/2021 | 09:47am EDT

Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the five-year patient-level meta-analysis of two major randomized controlled trials (RCTs). The findings, which represent the highest level of the evidence pyramid [1], confirm the long-term safety of the Philips Stellarex Drug-Coated Balloon (DCB). The meta-analysis shows no difference in mortality at each year through five years for patients treated with the Stellarex low-dose DCB when compared with those treated with percutaneous transluminal angioplasty (PTA), the current standard of care. The meta-analysis was presented at the 2021 Charing Cross International Symposium.

The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT meta-analysis comprises approximately 600 patients in Europe and the U.S., and is the largest homogenous patient data set of paclitaxel DCB RCTs with five-year follow-up [2,3]. After five years, the meta-analysis for the two studies shows no difference in survival rates, with 80.4% for the Stellarex DCB arm and 80.4% for the PTA arm. The analysis also demonstrates that the use of one or multiple Stellarex DCBs in a patient is not a predictor of mortality. The meta-analysis has a vital status follow-up compliance of over 90%.

'This meta-analysis confirms and reinforces the consistent and durable long-term safety profile of the low-dose Stellarex DCB through five years,' said William Gray, MD, FACC, FSCAI, and President of the Lankenau Heart Institute, an investigator for the Stellarex clinical trials who presented the results. 'The results are an important contribution to the long-term safety of paclitaxel-coated devices.'

We are committed to providing healthcare providers with accurate and transparent data to help them make an informed decision on the optimal treatment for each patient with peripheral arterial disease. With its low drug dose and unique drug coating composition, Stellarex is a logical choice for those who require this option.

Chris Landon

Senior Vice President and General Manager Image Guided Therapy Devices at Philips

'Stellarex is the only paclitaxel DCB to consistently demonstrate no difference in mortality every year through five years compared to PTA in multiple RCTs and in a patient-level meta-analysis,' said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. 'We are committed to providing healthcare providers with accurate and transparent data to help them make an informed decision on the optimal treatment for each patient with peripheral arterial disease. With its low drug dose and unique drug coating composition, Stellarex is a logical choice for those who require this option.'

Featuring Philips EnduraCoat technology, a unique coating consisting of a polyethylene glycol excipient with amorphous and crystalline paclitaxel particles dispersed in it, Philips Drug-Coated Balloon - Stellarex .035' is unlike any other DCB for the treatment of peripheral artery disease. EnduraCoat technology provides efficient drug transfer and effective drug residency coupled with high coating durability and minimal particulate loss, thereby enabling a low therapeutic drug dose.

Philips' Image Guided Therapy business provides complete procedural solutions of systems, smart devices, disease-specific software and services for minimally invasive procedures, helping caregivers decide, guide, treat and confirm the right therapy for each patient during their procedure.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries.

Contact:

Fabienne van der Feer

Philips Image Guided Therapy

Tel: + 31 622 698 001

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about KONINKLIJKE PHILIPS N.V.
05/07KONINKLIJKE PHILIPS N  : MedShare to Give Expectant Mothers in Underserved Bay A..
BU
05/06Philips Annual General Meeting of Shareholders approves all proposals
GL
05/06KONINKLIJKE PHILIPS N  : Royal Philips Renews Partnership With Circular Economy ..
MT
05/06KONINKLIJKE PHILIPS N  : Philips renews strategic partnership with Ellen MacArth..
PU
05/05KONINKLIJKE PHILIPS N  : Philips' Future Health Index 2021 report reveals transf..
AQ
05/05KONINKLIJKE PHILIPS N  : Connect America Buying Royal Philips' Aging, Caregiving..
MT
05/04Philips Foundation publishes its 2020 Annual Report highlighting the deployme..
GL
04/29Q1 2021 RESULTS : Philips CEO Frans van Houten on Bloomberg TV and CNBC
PU
04/29KONINKLIJKE PHILIPS N  : How can we drive circular economy to scale?
PU
04/29PHILIPS NV  : Berenberg remains its Buy rating
MD
More news
Financials
Sales 2021 17 809 M 21 659 M 21 659 M
Net income 2021 1 256 M 1 528 M 1 528 M
Net Debt 2021 4 175 M 5 078 M 5 078 M
P/E ratio 2021 35,0x
Yield 2021 1,92%
Capitalization 42 666 M 51 855 M 51 890 M
EV / Sales 2021 2,63x
EV / Sales 2022 2,44x
Nbr of Employees 81 592
Free-Float 98,4%
Chart KONINKLIJKE PHILIPS N.V.
Duration : Period :
Koninklijke Philips N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KONINKLIJKE PHILIPS N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 53,20 €
Last Close Price 48,07 €
Spread / Highest target 25,4%
Spread / Average Target 10,7%
Spread / Lowest Target -12,6%
EPS Revisions
Managers and Directors
NameTitle
Frans van Houten Chief Executive Officer
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Jeroen van der Veer Chairman-Supervisory Board
Jan Kimpen Chief Medical Officer
Sophie Bechu Chief Operating Officer & Executive Vice President
Sector and Competitors